硫酸羟氯喹(Hydroxychloroquine Sulfate) - 在研适应症：盘状红斑狼疮，疟疾，皮肤红斑狼疮_专利_临床

概要

基本信息

药物类型

小分子化药

别名

(±)-hydroxychloroquine、2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol、2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol

+ [23]

靶点-

作用方式

抑制剂

作用机制

细胞自噬抑制剂

治疗领域

免疫系统疾病感染皮肤和肌肉骨骼疾病+ [7]

在研适应症

盘状红斑狼疮疟疾皮肤红斑狼疮+ [10]

非在研适应症

新型冠状病毒感染原发性干燥综合征

原研机构

Sanofi

在研机构

上海中西三维药业有限公司Sanofi KK

Novartis Pharmaceuticals Corp.

+ [9]

非在研机构

SanofiPulmoquine Therapeutics, Inc

Scandibio Therapeutics AB

+ [1]

权益机构

Covis Pharma Holdings BV

Sanofi-Aventis U.S. LLC

最高研发阶段批准上市

首次获批日期

美国 (1955-04-18),

急性疟疾类风湿关节炎系统性红斑狼疮

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C18H28ClN3O5S

InChIKeyJCBIVZZPXRZKTI-UHFFFAOYSA-N

CAS号747-36-4

关联

672

项与硫酸羟氯喹相关的临床试验

NCT05842174

/ Not yet recruiting临床1/2期IIT

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Through Image-guided Locoregional Therapy

Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and then blocking the artery with embolics in order to kill tumor cells by depriving them of essential oxygen and nutrients. While TACE has a proven survival benefit, local recurrence is common, and long-term survival rates are poor. Prior studies demonstrate that HCC cells survive the oxygen and nutrient deprivation through autophagy, a process of cellular self-eating, to provide nutrients required for survival. The proposed project will leverage this dependency to develop a novel approach to TACE that integrates autophagy inhibition to improve therapeutic response by increasing tumor cell killing and enhancing anti-tumor immunity.

开始日期2025-10-01

申办/合作机构

VA Office of Research and Development

NCT06408298

/ Not yet recruiting早期临床1期IIT

A Randomized, Placebo Controlled Proof of Principle (Window of Opportunity) Study of Hydroxychloroquine (HCQ) in Prostate Cancer Patients Undergoing Radical Prostatectomy

This is randomized, double blind, placebo controlled proof of principle (window of opportunity) study of oral hydroxychloroquine in patients with resectable localized prostate cancer. To determine the effects of hydroxychloroquine (HCQ) on markers of autophagy, such as p62, LC3-II and NBR-1 in prostate cancer tissue of patients with resectable localized prostate cancer who undergo radical prostatectomy. To monitor/observe the safety and tolerability of daily oral hydroxychloroquine in the pre and perioperative period in patients who undergo radical prostatectomy. To evaluate the concentration of hydroxychloroquine in normal and prostate tumor tissue and to correlate prostate tissue concentrations with the plasma concentrations in these patients. To perform tumor genomic analysis (for common somatic mutations) and to correlate the molecular response to HCQ and presence/absence of such mutations.

开始日期2025-09-01

申办/合作机构

Dartmouth-Hitchcock Medical Center

NCT06971744

/ Not yet recruiting临床2期

Autophagy Maintenance (AUTOMAIN) Therapy in High-Grade Serous Ovarian Cancer: A Phase II Trial

This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and nelfinavir mesylate (NFV) will benefit ovarian cancer patients in a maintenance setting. Patients will receive the two study drugs HCQ and NFV in combination with maintenance bevacizumab.

开始日期2025-09-01

申办/合作机构

The Medical University of South Carolina

100 项与硫酸羟氯喹相关的临床结果

登录后查看更多信息

100 项与硫酸羟氯喹相关的转化医学

登录后查看更多信息

100 项与硫酸羟氯喹相关的专利（医药）

登录后查看更多信息

13,808

项与硫酸羟氯喹相关的文献（医药）

2026-01-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Isolated lumbar vertebral infection caused by Coxiella burnetii: A case report and literature review

Article

作者: Ma, Xuzhu ; Wang, Xiaohui ; Xin, Mingming ; Lin, Minggui

This study describes the clinical characteristics and treatment of vertebral infection caused by Coxiella burnetii through a case report and literature review. We present a 60-year-old male with isolated lumbar vertebral infection. A comprehensive literature review identified 17 cases, with 82.4 % of patients over 50 years old. Common symptoms included lumbar pain and fever, while 52.9 % developed adjacent vertebral infections through abdominal aortic aneurysms. Only 17.6 % presented as isolated vertebral infections. Radiological evidence of vertebral destruction was observed in all cases, with no cardiac valve involvement. Treatment involved doxycycline, hydroxychloroquine, fluoroquinolones, rifampicin, and surgical intervention, resulting in favorable outcomes. Isolated vertebral infections caused by Coxiella burnetii are extremely rare and pose significant diagnostic challenges. Early surgical intervention, effective diagnostic methods, and standardized anti-infective therapy are crucial for management. This case highlights the importance of timely diagnosis and multidisciplinary treatment for this rare condition.

2025-12-31·ANNALS OF MEDICINE

Comparative outcomes of COVID-19 in patients with primary Sjögren’s syndrome treated with hydroxychloroquine versus methotrexate: a retrospective cohort study

Article

作者: Liu, Li-Teh ; Tsai, Jih-Jin ; Wei, James Cheng-Chung ; Liao, Pei-Lun

BACKGROUND:

People with rheumatic diseases are considered at risk for severe coronavirus disease 2019 (COVID-19) because of their underlying abnormal immune responses and frequent disease-modifying antirheumatic drug (DMARD) use. We aimed to explore COVID-19 outcomes in patients with primary Sjögren's syndrome (pSS) receiving different conventional synthetic DMARDs.

METHODS:

The study was a retrospective analysis of real data from the TriNetX platform between 1 January 2020 and 30 June 2023. We compared COVID-19 outcomes between cohorts of pSS patients treated with hydroxychloroquine (HCQ) and methotrexate (MTX).

RESULTS:

After propensity score matching, 1045 and 1045 pSS patients in the HCQ and MTX cohorts were included in the analysis. Our study revealed that the risk of COVID-19 in the HCQ cohort was significantly 25.9% lower than that in the MTX cohort. Among 18-64-year-old patients and unvaccinated patients, those in the HCQ cohort had a significantly lower risk of contracting COVID-19 than did those in the MTX cohort. Regarding the comorbidities of chronic kidney disease and neoplasms, the HCQ cohort had a significantly lower risk of adverse outcomes than the MTX cohort.

CONCLUSIONS:

This is the first study in which a significant number of pSS patients was enrolled and head-to-head to compare the risk of COVID-19 incidence and adverse outcomes between those receiving HCQ and those receiving MTX, and we concluded that the risk of COVID-19 incidence was significantly lower in the HCQ cohort than in the MTX cohort. However, there were no significant differences in adverse COVID-19 outcomes between the cohorts.

2025-12-01·JOURNAL OF CLINICAL IMMUNOLOGY

Diverse Clinical and Immunological Profiles in Patients with IPEX Syndrome: a Multicenter Analysis from Turkey

Article

作者: Bozkurt, Selcen ; Bilgic Eltan, Sevgi ; Yalcin Gungoren, Ezgi ; Bayram Catak, Feyza ; Kiykim, Ayca ; Can, Salim ; Amirov, Razin ; Baris, Safa ; Ozen, Ahmet ; Bal Cetinkaya, Fatma ; Bekis Bozkurt, Hayrunnisa ; Catak, Mehmet Cihangir ; Sahin, Ali ; Yorgun Altunbas, Melek ; Kasap, Nurhan ; Ozturk, Necmiye ; Yakici, Nalan ; Gemici Karaarslan, Betul ; Orhan, Fazil ; Cavkaytar, Ozlem ; Arga, Mustafa ; Karakoc-Aydiner, Elif

PURPOSE:

Immunodysregulation, Polyendocrinopathy, Enteropathy, and X-linked syndrome (IPEX), caused by pathogenic FOXP3 variants, is a rare autoimmune disorder with diverse clinical features, including early-onset diabetes, eczema, and enteropathy. Atypical cases show milder symptoms and unique signs, requiring different treatments. Therefore, there are ambiguities in the accurate diagnosis and management of IPEX. We sought to present clinical, genetic, and immunological assessments of 12 IPEX patients with long-term follow-up to facilitate the diagnosis and management of the disease.

METHODS:

Clinical findings and treatment options of the patients were collected over time. Lymphocyte subpopulations, protein expressions, regulatory T (Treg) and circulating T follicular helper (cT_FH) cells, and T-cell proliferation were analyzed.

RESULTS:

Predominant presentations included autoimmunity (91.6%), failure to thrive (66.7%), and eczema (58.3%). There were four classical and eight atypical IPEX individuals. Allergic manifestations were more common in atypical patients. Notably, chronic diarrhea demonstrated heightened severity compared to other manifestations. Four patients (33.3%) demonstrated eosinophilia, and nine (75%) showed high serum IgE levels. Most patients exhibited normal percentages of Treg cells with reduced CD25, FOXP3, and CTLA-4 expressions, corrected after hematopoietic stem cell transplantation (HSCT). Compared to healthy controls, the T_H2-like skewing accompanied by reduced T_H17-like responses was observed in cT_FH and Treg cells of patients. Overall, nine patients (75%) received immunosuppressants (ISs), and six (50%) underwent HSCT, which was the only treatment revealing sustained control. Sirolimus was used in six patients and showed better control than other ISs.

CONCLUSIONS:

The first cohort from Turkey with long-term follow-up results, comparing typical and atypical cases, provides insights into the outcomes of different therapeutic modalities and T- cell subtype changes in IPEX syndrome.

335

项与硫酸羟氯喹相关的新闻（医药）

2025-09-08

·奇点网

《自然·医学》：预防乳腺癌复发的药物出现了！科学家发现，抑制自噬和mTOR通路可减少休眠肿瘤细胞存活，三年无复发生存率达100%

*仅供医学专业人士阅读参考乳腺癌是全球最常见的癌症之一，尽管大多数患者在初期得到有效治疗，然而20%至30%的患者在治疗后会因隐匿性微小残留疾病而复发。微小残留病变中的休眠性弥散肿瘤细胞（DTCs）被认为是乳腺癌复发的根源，这些细胞能够在体内潜伏多年，直到条件合适时重新激活并引发复发。科学家们发现，通过靶向这些休眠肿瘤细胞，或许可以有效阻止乳腺癌的复发。近日，一篇发表在《自然·医学》的论文提出，一些“老药”可以把这些漏网之鱼逮捕归案！美国宾夕法尼亚大学的Lewis A. Chodosh、Angela DeMichele等人完成了这项重要研究。他们先是在乳腺癌小鼠实验中发现，使用氯喹抑制细胞自噬或使用雷帕霉素抑制mTOR信号通路，可以破坏休眠肿瘤细胞的苟且偷生之计，延长小鼠肿瘤复发时间，两种方案联合使用效果更好。随后他们在197名乳腺癌幸存者中展开了临床试验，测试了安全性更优的羟氯喹与依维莫司的治疗可行性。结果显示，羟氯喹与依维莫司联合治疗下，患者的三年无复发生存率达到了100%，休眠肿瘤细胞的清除率也高达87%。论文首页截图为了解休眠肿瘤细胞（DTCs）的逃跑路线，研究者们在临床前研究阶段给小鼠注射HER2诱导型肿瘤细胞，并通过控制多西环素（Dox）来调节HER2的表达；当多西环素撤除时，HER2表达下调，原发乳腺癌肿瘤消退，肿瘤细胞从增殖状态转为休眠状态。由此得到的小鼠DTCs，其基因表达变化与乳腺癌患者的残余疾病相似，且与复发风险密切相关。研究者们发现，肿瘤细胞从增殖状态转为休眠状态时，伴随自噬活性的增加。使用基因编辑技术删除Atg5、Atg7、Becn1等自噬关键基因，或者采取针对自噬的药理学抑制，比如长期给予小鼠氯喹（CQ），可以明显抑制DTCs的生存，提高乳腺癌小鼠的无复发生存期。氯喹属于氨基喹啉类药物，能够通过抑制溶酶体的功能（降低酸性环境），阻碍自噬体与溶酶体的融合，从而发挥自噬抑制剂的作用。除了采用自噬抑制剂，研究者们发现抑制mTOR信号通路也能给DTCs带来生存压力。mTOR通路从多个维度掌管着细胞的生死大权，包括生长、增殖、代谢，以及自噬。虽然观察到DTCs为了生存偷偷略微下调了mTOR通路的活性，但小鼠实验结果显示，通过药理学极大抑制mTOR通路活性，不仅可以抑制乳腺癌细胞的增殖，对于残余下来的DTCs的生存而言也是沉重打击。使用mTOR抑制剂雷帕霉素治疗小鼠时，能够有效减少DTCs的存活并延缓复发。在进一步的前临床研究中，研究者们通过使用羟氯喹（HCQ）和依维莫司（EVE）来分别抑制自噬和mTOR信号通路。HCQ已被广泛用于治疗自身免疫疾病，并且相较于CQ，HCQ具有更好的安全性，而EVE作为FDA批准的mTOR抑制剂，已用于治疗晚期乳腺癌。通过比较不同治疗方案对DTCs的影响，研究者们发现，单独使用HCQ、EVE以及它们的联合治疗，都能够显著减少DTCs数量，延缓肿瘤复发。在小鼠模型中，研究者还进一步探讨了治疗持续时间对效果的影响。研究表明，治疗持续时间越长，肿瘤细胞负担减少的效果越明显，特别是在EVE和HCQ的联合治疗组中，随着治疗周期的延长，复发的时间显著延迟。这表明，针对DTCs的治疗效果与药物治疗的持续时间密切相关。通过这些临床前研究，研究者们证明了靶向DTCs自噬活性和mTOR信号通路的潜力，并为临床转化提供了有力的理论支持。为了将这些发现应用到临床，研究者们设计并实施了CLEVER临床试验。该试验共招募197名乳腺癌幸存者，且在诊断后5年内，骨髓检测显示存在可检测到的DTCs。试验将患者随机分为四组：一组接受HCQ治疗，另一组接受EVE治疗，还有一组接受HCQ与EVE的联合治疗，最后一组患者在经过3个月观察后，才开始联合治疗。研究结果表明，HCQ、EVE及两者联合治疗均具有较好的治疗耐受性，且仅有一名患者因毒性反应中断了治疗。经过42个月的中位随访，HCQ、EVE和HCQ+EVE组的3年无复发生存率（RFS）分别为91.7%、92.9%和100%。在所有接受治疗的患者中，那些成功清除了DTCs的患者，其RFS显著提高。三组中，联合治疗组显示出最高的DTC减少率，达到87%。这项研究的结果为靶向DTCs的治疗策略提供了有力的证据。研究表明，无论是单独使用HCQ和EVE，还是两者联合使用，都能够有效减少DTCs的数量，并在一定程度上提高RFS。基于这些新发现，靶向DTCs的治疗策略或将成为乳腺癌复发预防的新武器，带来更广阔的临床应用前景。需要注意的是，HCQ和EVE的联合治疗虽然能够更好地清除DTCs，但其耐受性和副作用也不容忽视，尤其是在联合治疗中，部分患者出现了较为明显的毒性反应。因此，未来需要进行更大规模的随机对照试验，以进一步验证这些治疗策略的有效性，并优化治疗方案，减轻副作用。参考文献： [1]DeMichele, A., Clark, A.S., Shea, E. et al. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial. Nat Med (2025). https://doi.org/10.1038/s41591-025-03877-3 本文作者丨张艾迪

临床研究

2025-08-26

·医药经济报

327个药品被暂停挂网，重点监控名单更新，中成药集采续约

辽宁公布第十批国采未中选药品梯度降价结果 8月25日，辽宁省发布《关于公布并执行第十批国家组织药品集中采购未中选药品梯度降价结果的通知》，公布了614个符合梯度降价标准的药品以及327个不符合梯度降价标准的药品名单。通知明确，对自主申报价格符合梯度降价标准的第十批国家组织药品集中采购未中选药品予以公布，降价结果于2025年8月26日零时起执行。对于自主申报价格不符合梯度降价标准的药品，暂停挂网采购。暂停挂网采购的药品，企业自主降价并符合梯度降价标准后，可申请恢复挂网。此次公布的符合梯度降价标准的药品清单中，拜耳的阿司匹林肠溶片、梯瓦的甲磺酸雷沙吉兰片、赛诺菲的硫酸羟氯喹片等39个参比制剂都按照相关要求降价。而在不符合梯度降价标准药品清单中，UCB的拉考沙胺注射液、欧加农（Organon）的磷酸西格列汀片、意大利赞邦集团（Zambon S.p.A）的乙酰半胱氨酸泡腾片等多个外企品种被列入其中。 15个药被重点监控 8月25日，上海阳光医药采购网发布《关于公布2025年6月药品挂网公开议价采购监管品种名单的通知》，公布了6月新申请超“黄线”、原在库超“黄线”、未通过公允性，以及重点监控各10个品种，共40个品种。通知显示，2025年6月挂网公开议价超“黄线”、未通过公允性评估、重点监控药品幅度靠前且有一定采购金额的品种，并指出，公布品种仅作为提醒，请各医疗机构根据市场供需情况以及阳光平台“红黄绿线”议价实时提醒信息合理议价，既保证临床需求，又避免不合理调价，采购质量可靠、价格适宜的药品。北京启动2022年中成药带量采购项目期满接续采购近日，北京市医保局发布《关于开展2022年北京市中成药带量采购项目谈判药品期满接续采购有关工作的通知》，由于2022年北京市中成药带量项目采购范围内带量联动药品已参加全国中成药联盟集采，现组织对其余协议期满的带量谈判药品开展接续采购。明确采购周期至2027年12月31日。根据《带量谈判药品目录》全国带量采购中选结果，带量联动其现行全国各省级或省际联盟带量采购中选价格水平，按照不同企业分包带量的方式，经购销双方互相选择，确定中选药品，实行带量采购。编辑：陈丽娜版式编辑：陈淑文审校：马飞、张松赖诗卿、宣建伟、殷劲群等专家、企业代表畅谈商保目录申报要点 “十四五”中药创新药已批27个！扬子江、绿叶、海博特共议高质量发展破局点不降价就禁用！中成药价格治理加码，太极、片仔癀等巨头业绩大考 www.yyjjb.com.cn 洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店

带量采购

2025-08-14

·米内网

【关注】超49亿重磅品种，国药集团发起冲击

精彩内容近日，CDE官网显示，国药集团提交的4类仿制药沙库巴曲缬沙坦钠片、3类仿制药注射用硫酸多黏菌素B上市申请获受理。在中国三大终端六大市场（统计范围详见本文末），沙库巴曲缬沙坦钠片、注射用硫酸多黏菌素B销售额峰值分别超49亿元和18亿元。来源：CDE官网沙库巴曲缬沙坦钠片是由沙库巴曲（脑啡肽酶抑制剂）和缬沙坦（血管紧张素Ⅱ受体拮抗剂）组成的复方制剂，目前已纳入国家医保乙类药目录，限制使用范围：①射血分数降低的慢性心力衰竭成人患者；②原发性高血压。在中国三大终端六大市场，沙库巴曲缬沙坦钠片近年来销售额持续攀升，2024年拿下创新高的超49亿元；2025Q1继续以17.27%的增速增长至约15亿元，为高血压化药TOP1产品。目前该药已有27家企业（本土25家、进口2家）拥有生产批文，石药集团、正大天晴药业、国药集团等60余家企业以新分类提交上市申请，其中有26家已获批上市、视同过评。近年来中国三大终端六大市场沙库巴曲缬沙坦钠片销售趋势（单位：万元）来源：米内网格局数据库注射用硫酸多黏菌素B是一种从多黏芽孢杆菌中分离出的抗菌性多肽，可用于绿脓杆菌及其他假单胞菌引起的创面、尿路以及眼、耳、气管等部位感染，也可用于败血症、腹膜炎等，2022年在中国三大终端六大市场销售额达到峰值超18亿元，随后近三年均有所下滑。米内网数据显示，目前国内仅有汇宇制药、倍特药业等4家企业的注射用硫酸多黏菌素B获批上市，20余家企业的产品以新分类报产在审，包括齐鲁制药、桂林南药、海南双成药业、福安药业、国药集团等。注射用硫酸多黏菌素B新分类报产在审情况来源：米内网中国申报进度（MED）数据库今年以来，国药集团已有近30款高端仿制药提交上市申请在审，涉及玻璃酸钠滴眼液、酒石酸布托啡诺注射液、硫酸羟氯喹片、莫匹罗星软膏、重酒石酸间羟胺注射液等2024年在中国三大终端六大市场销售额超10亿元的重磅品种，覆盖感觉系统药物、神经系统药物、肌肉-骨骼系统等治疗大类。资料来源：米内网数据库、CDE官网注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至8月14日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准引进/卖出

100 项与硫酸羟氯喹相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02114	硫酸羟氯喹	P01BA02	DB01611

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
盘状红斑狼疮	美国	Novitium Pharma LLC	2022-01-14
疟疾	美国	Novitium Pharma LLC	2022-01-14
皮肤红斑狼疮	日本	Sanofi KK	2015-07-03
急性疟疾	美国	Advanz Pharma Corp. Ltd.	1955-04-18
类风湿关节炎	美国	Advanz Pharma Corp. Ltd.	1955-04-18
系统性红斑狼疮	美国	Advanz Pharma Corp. Ltd.	1955-04-18

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	临床3期	美国	Novartis Pharmaceuticals Corp.	2020-05-01
原发性干燥综合征	临床3期	法国	Sanofi	2008-03-01
转移性胰腺癌	临床2期	爱尔兰	Novartis AG	2023-05-31
胰腺腺癌	临床2期	美国	West Virginia University Hospitals, Inc.	2020-02-04
转移性胰腺腺癌	临床1期	美国	Novartis Pharmaceuticals Corp.	2019-01-18
不能切除性胰腺癌	临床1期	美国	Novartis Pharmaceuticals Corp.	2019-01-18
乳腺癌	临床前	美国	Berry Consultants LLC	2025-09-02
乳腺癌	临床前	美国	University of Pennsylvania	2025-09-02
睡眠呼吸暂停综合征	临床前	美国	University of Texas Health Science Center At San Antonio	2025-06-20
肾脏损伤	临床前	中国	东南大学附属中大医院	2017-05-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03032406 (CLEVER, Pubmed \| Nat Med)	临床2期	乳腺癌	51	Hydroxychloroquine (HCQ)	廠遞構蓋築鹹簾糧淵遞(窪夢襯鹽鏇築鹹遞鏇蓋) = 鹽夢顧齋襯餘鏇夢糧蓋蓋範醖壓範餘齋鹹鹽鏇 (積簾築積膚構夢網鑰鹹 )	积极	2025-09-02
				Everolimus (EVE)	廠遞構蓋築鹹簾糧淵遞(窪夢襯鹽鏇築鹹遞鏇蓋) = 觸網膚夢範簾鏇選鬱憲蓋範醖壓範餘齋鹹鹽鏇 (積簾築積膚構夢網鑰鹹 )
NCT02603146 (Pubmed \| Arthritis Rheumatol)	临床2期	类风湿关节炎	144	Hydroxychloroquine	積齋積鬱鏇窪鹹繭獵艱(範範廠築夢壓鹹範築願) = 鬱衊鑰餘鏇製製夢壓選選遞鑰製鹽積廠繭繭膚 (蓋構膚窪醖衊淵簾範遞 )	不佳	2025-08-29
				Placebo	積齋積鬱鏇窪鹹繭獵艱(範範廠築夢壓鹹範築願) = 蓋鹽鬱衊積簾壓壓繭壓選遞鑰製鹽積廠繭繭膚 (蓋構膚窪醖衊淵簾範遞 )
NCT03030118 (SMILE, CTgov)	临床2期	系统性红斑狼疮	187	Hydroxychloroquine (Hydroxychloroquine)	窪繭鹹蓋選壓範廠窪鹽 = 網積襯獵壓窪顧簾憲膚遞窪醖襯餘壓襯簾範製 (壓構蓋糧觸壓網衊製獵, 顧艱鏇廠淵窪淵遞齋餘 ~ 壓網鏇餘憲繭齋壓壓蓋) 更多	-	2025-08-29
				Placebo Oral Capsule (Placebo Oral Capsule)	窪繭鹹蓋選壓範廠窪鹽 = 鏇艱構願膚願繭襯鹽餘遞窪醖襯餘壓襯簾範製 (壓構蓋糧觸壓網衊製獵, 獵簾觸鹹鹹願築網衊獵 ~ 糧鹹憲醖夢構糧鬱壓醖) 更多
EULAR2025	N/A	银屑病关节炎	13,710	Hydroxychloroquine (HCQ) users	顧壓獵範鏇獵醖築膚構(積淵鑰壓膚繭積鏇糧衊): RR = 0.833 (95.0% CI, 0.7 ~ 0.992), P-Value = 0.04 更多	积极	2025-06-11
				Non-HCQ users
NCT04011410 (CTgov)	临床2期	复发性前列腺癌 \| 寡转移性前列腺癌	20	Hydroxychloroquine Sulfate 200Mg Tab	糧齋淵醖蓋積遞構範艱 = 艱醖鏇餘醖製蓋窪蓋網鹹鹽廠繭淵壓顧願餘憲 (衊壓築築窪遞築遞糧壓, 鏇膚範壓憲艱壓蓋醖鏇 ~ 顧餘鹹範願積憲齋鏇醖) 更多	-	2025-04-11
NCT03032406 (CLEVER, CTgov)	临床2期	复发性乳腺癌	53	Hydroxychloroquine (HCQ Alone (Arm A))	鏇壓鹽鑰鏇繭壓蓋簾壓 = 選襯製蓋鏇襯齋願願鹹壓鏇簾願範觸糧憲壓鏇 (膚鬱醖繭壓衊壓襯襯艱, 網糧淵鑰鹽壓積鹹淵壓 ~ 鑰醖遞艱願膚憲蓋壓壓) 更多	-	2025-03-05
				Everolimus (EVE Alone (Arm B))	鏇壓鹽鑰鏇繭壓蓋簾壓 = 淵積願觸製糧膚鏇憲糧壓鏇簾願範觸糧憲壓鏇 (膚鬱醖繭壓衊壓襯襯艱, 淵網鹹窪衊築鏇鏇範廠 ~ 鬱積鬱築鹹壓遞獵顧廠) 更多
NCT03774472 (CTgov)	临床1/2期	ER阳性/HER2阴性乳腺癌 \| 转移性乳腺癌	15	HCQ (HCQ at 400 mg)	願積獵衊鑰觸艱築網製 = 壓顧鹹齋製膚醖範窪選壓獵艱築廠膚糧繭憲襯 (範觸觸淵齋壓衊鹽艱鑰, 遞觸憲糧齋壓廠醖膚廠 ~ 壓襯窪憲糧糧獵繭淵淵) 更多	-	2025-02-17
				HCQ (HCQ at 600 mg)	願積獵衊鑰觸艱築網製 = 淵窪製繭糧糧膚糧構膚壓獵艱築廠膚糧繭憲襯 (範觸觸淵齋壓衊鹽艱鑰, 淵顧範積簾膚鬱範製艱 ~ 壓遞構觸壓鹽鏇衊醖鹹) 更多
NCT04011410 (ASCO_GU2025) 人工标引	临床2期	寡转移性前列腺癌	19	Hydroxychloroquine 400 mg	遞觸膚餘窪築積鑰襯鏇(鹹鹹膚簾繭鬱範繭簾壓) = 鑰窪壓獵築襯憲顧遞簾築艱蓋鏇淵艱餘築蓋構 (顧壓網範獵簾憲夢構積, 6.4 ~ N/A) 更多	积极	2025-02-13
NCT03037437 (ASCO_GI2025)	临床2期	晚期肝细胞癌一线	33	Sorafenib 400 mg po BID + Hydroxychloroquine 400 mg daily	壓艱構壓繭窪願網夢築(簾膚壓選顧齋遞選製簾) = 艱築選製鹹憲製積築壓獵窪鏇醖衊顧製衊糧選 (選糧製窪鹹築廠觸築網, 4.0 ~ 19.0) 更多	积极	2025-01-23
NCT05953350 (Pubmed) 人工标引	临床1/2期	HR阳性/HER2阴性乳腺癌二线	29	HCQ + Palbociclib	範鏇構鑰顧醖膚選網觸(簾窪鹹憲鑰範艱選鹽淵) = no DLT in patients treated with hydroxychloroquine (HCQ; 600 mg, bis in die [bid]) plus increasing doses of palbociclib (100, 150, or 200 mg, quaque die [qd]). 艱膚糧遞構膚獵鏇範鏇 (夢鏇選糧窪鏇糧繭鹽遞 ) 更多	积极	2024-12-23